Navigation Links
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Date:5/20/2008

HAYWARD, Calif., May 20 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced the appointment of Pamela S. Cohen, M.D., as Senior Vice President and Chief Medical Officer. Dr. Cohen is a recognized expert in the global development and registration of cancer therapeutics and has had a long and distinguished career as a medical oncologist and clinical pharmacologist, most notably at Novartis. Dr. Cohen joins Kosan from GE Healthcare Medical Diagnostics where she served as the Global Oncology Therapeutic Area Head, responsible for strategic development, clinical trial implementation and registration of the GE Healthcare-Medical Diagnostics Division's product portfolio of molecularly targeted imaging diagnostics.

"Pam's extensive experience in leading all aspects of cancer drug development and registration in worldwide markets and her work with a broad range of compound classes and tumor types will be of significant value to Kosan as we advance our Hsp90 inhibitor and epothilone programs through later stages of development," said Helen S. Kim, Kosan's President and Chief Executive Officer. "Recruiting an experienced and accomplished chief medical officer was one of Kosan's major goals for 2008. We are delighted that Pam will be able to leverage her direct knowledge of cytotoxic and targeted oncology drug development to bring leadership, direction and focus to the execution of Kosan's development activities. Pam is well-known and respected throughout the oncology community as well as the pharmaceutical industry, and she will be instrumental in strengthening our partnering initiatives. Kosan's Board of Directors and management team join me in welcoming Pam to Kosan."

Dr. Cohen has been involved in
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
2. Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
3. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
4. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
5. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
6. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
7. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
8. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
9. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
10. Kosan Announces February 28, 2008 Conference Call and Webcast
11. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 The laboratory information management ... witnessed a number of technological advancements due to factors ... growing need to integrate healthcare systems, and increasing government ... in system integration. Key players in the market focus ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... DE (PRWEB) January 22, 2015 Controlled ... Pistoia Alliance, which helps companies check the legal requirements ... to expand to China. , As their international ... are globally adopting software solutions built as a result ...
(Date:1/22/2015)... Nueva Jersey , 22 de enero de 2015 ... Research abre hoy su llamada a nominaciones para 2015. ... científica ha hecho, o tiene el potencial para hacer, ... Las nominaciones se aceptarán hasta el 15 de marzo ...
Breaking Biology Technology:Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Global Compliance Service for Controlled Substances to Expand to China 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... 25 Years of Life ... Sciences Industry Experience, RANCHO CORDOVA, Calif., Aug. ... innovative products that,process and store adult stem cells, said today that ... America, has been named to the Company,s Board of,Directors. Her appointment ...
... AEterna Zentaris Inc.,(NASDAQ: AEZS , TSX: AEZ), ... oncology, will announce its second quarter 2008,financial and ... 12,2008. The Company will host a conference call ... day at 4:30 p.m., Eastern Time., Participants ...
... $623 Million; GAAP EPS $0.53; Adjusted EPS $0.48, ... WPI ), a leading specialty pharmaceutical,company, today reported financial ... Second Quarter 2008 Results, Net revenue for the ... $60.3 million, or $0.53 per diluted share. Net income ...
Cached Biology Technology:ThermoGenesis Names Tiffany Olson to Board of Directors 2ThermoGenesis Names Tiffany Olson to Board of Directors 3Watson Pharmaceuticals Reports Second Quarter 2008 Results 2Watson Pharmaceuticals Reports Second Quarter 2008 Results 3Watson Pharmaceuticals Reports Second Quarter 2008 Results 4Watson Pharmaceuticals Reports Second Quarter 2008 Results 5Watson Pharmaceuticals Reports Second Quarter 2008 Results 6Watson Pharmaceuticals Reports Second Quarter 2008 Results 7Watson Pharmaceuticals Reports Second Quarter 2008 Results 8Watson Pharmaceuticals Reports Second Quarter 2008 Results 9Watson Pharmaceuticals Reports Second Quarter 2008 Results 10Watson Pharmaceuticals Reports Second Quarter 2008 Results 11Watson Pharmaceuticals Reports Second Quarter 2008 Results 12Watson Pharmaceuticals Reports Second Quarter 2008 Results 13Watson Pharmaceuticals Reports Second Quarter 2008 Results 14Watson Pharmaceuticals Reports Second Quarter 2008 Results 15Watson Pharmaceuticals Reports Second Quarter 2008 Results 16Watson Pharmaceuticals Reports Second Quarter 2008 Results 17
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading ... the launch of its new website design. "When ... its infancy", says Peter O,Neill , founder and CEO ... the industry needs involvement from the key players on a ...
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
(Date:1/22/2015)... 2015  A man-made form of insulin delivered by nasal ... in adults with mild cognitive impairment and Alzheimer,s disease ... at Wake Forest Baptist Medical Center. The ... cognitive impairment (MCI) or mild to moderate Alzheimer,s dementia ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... were made whole again by bone tissue grown from ... defects (defects that would not otherwise heal on their ... forms the skull, is a vivid demonstration of new ... use hESCs for tissue regeneration. Using mesenchymal ...
... (December 1, 2007) Damaged or defective genes have ... cancers. Over the past decade, however, scientists have discovered ... off and can cause cancer without any changes in ... poorly understood. Researchers in the laboratory of ...
... Water chemistry and mineralogy are scientific fields that have ... technologies. The boundary of water and rock, however, is ... field of nanoparticle science. Scientists are discovering that ... and engineered water chemistry and systems differently than similar ...
Cached Biology News:Human embryonic stem cell -- derived bone tissue closes massive skull injury 2DNA methylation shown to promote development of colon tumors 2DNA methylation shown to promote development of colon tumors 3Between water and rock -- a new science 2Between water and rock -- a new science 3Between water and rock -- a new science 4Between water and rock -- a new science 5
...
... siSolutions siRNA Custom Synthesis Service ... duplex RNA to knockdown any ... (19 RNA base pairs with ... 27-mers, or other lengths of ...
... to CRF The antibody ... CRF sequence that it was ... are found in the paraventricular ... in colchicine treated 4% FA ...
...
Biology Products: